The Novartis Business Development and Licensing team is behind many of the partnerships that fuel our innovation.
A pair of exceptionally large proteins provide the framework for synaptic connections.
Experimental treatments for Alzheimer’s disease put the amyloid cascade hypothesis to the test.
We surveyed 7,000 people in seven countries to find out what they know about multiple sclerosis (MS). Our survey identified several surprising misconceptions.
Addressing four measures of disease progression in relapsing MS could help preserve physical and cognitive function.
Making clinical tools from basic research knowledge is a practice Novartis and FMI researchers pursue. Read how they want to help retinitis pigmentosa patients to see the light.
Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.
This site is intended for a global audience.